Horizon Tech Finance Pref Shares HTFB 4.875 03/30/26 | 10-Q: FY2025 Q1 EPS: USD -0.53

EPS: As of FY2025 Q1, the actual value is USD -0.53.

Segment Revenue

• Investment Income: Total investment income for the three months ended March 31, 2025 was $24,516, compared to $26,129 for the same period in 2024.

Operational Metrics

• Net Investment Income: Net investment income before excise tax for the three months ended March 31, 2025 was $11,097, compared to $12,984 for the same period in 2024.
• Net Realized and Unrealized Loss: Net realized and unrealized loss for the three months ended March 31, 2025 was -$32,155, compared to -$3,952 for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: Net cash used in operating activities for the three months ended March 31, 2025 was -$13,185, compared to $4,041 provided by operating activities for the same period in 2024.
• Net Cash Used in Financing Activities: Net cash used in financing activities for the three months ended March 31, 2025 was -$10,219, compared to -$8,430 for the same period in 2024.

Unique Metrics

• Distributable Loss: Distributable loss as of March 31, 2025 was -$216,873, compared to -$182,061 as of December 31, 2024.

Future Outlook and Strategy

• Core Business Focus: Horizon Technology Finance Corporation aims to continue focusing on secured debt and venture lending investments to venture capital-backed companies in technology, life science, healthcare information and services, cleantech, and sustainability industries.
• Non-Core Business: The company is involved in various sectors including biotechnology, medical devices, and sustainability, with investments in companies like Castle Creek Biosciences, Inc., Emalex Biosciences, Inc., and Pivot Bio, Inc.